• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

CombiGene AB Developing CG01 Gene Therapy for Epilepsy Treatment

Accelero is proud becoming a selected partner for the leading Nordic gene therapy company CombiGene AB (Lund) developing an AAV-based treatment targeting epilepsy.

Main purpose of the bioanalytical study package is the GLP compliant biodistribution and shedding analysis in cooperation with the CG01 project partner Northern Biomedical Research Inc. (Norton Shores, MI, United States). This includes  immunogenicity testing of the vector and its expression products.

Accelero will also be responsible for the sample import from North America into the European Union. All assays will be fully validated in compliance with the respective EMA and FDA guidelines for bioanalytical method validation.

Please feel free to follow this link for the complete CombiGene press release.